Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib
Ren, Xiaomei ; Pan, Xiaofen ; Zhang, Zhang ; Wang, Deping ; Lu, Xiaoyun ; Li, Yupeng ; Wen, Donghai ; Long, Huoyou ; Luo, Jinfeng ; Feng, Yubing ; Zhuang, Xiaoxi ; Zhang, Fengxiang ; Liu, Jianqi ; Leng, Fang ; Lang, Xingfen ; Bai, Yang ; She, Miaoqin ; Tu, Zhengchao ; Pan, Jingxuan ; Ding, Ke
刊名JOURNAL OF MEDICINAL CHEMISTRY
2013
卷号56期号:3
ISSN号0022-2623
学科主题Pharmacology & Pharmacy
语种英语
公开日期2016-12-16
内容类型期刊论文
源URL[http://ir.gibh.ac.cn/handle/344009/764]  
专题广州生物医药与健康研究院_华南干细胞与再生医学研究所_华南干细胞与再生医学研究所_期刊论文
推荐引用方式
GB/T 7714
Ren, Xiaomei,Pan, Xiaofen,Zhang, Zhang,et al. Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib[J]. JOURNAL OF MEDICINAL CHEMISTRY,2013,56(3).
APA Ren, Xiaomei.,Pan, Xiaofen.,Zhang, Zhang.,Wang, Deping.,Lu, Xiaoyun.,...&Ding, Ke.(2013).Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib.JOURNAL OF MEDICINAL CHEMISTRY,56(3).
MLA Ren, Xiaomei,et al."Identification of GZD824 as an Orally Bioavailable Inhibitor That Targets Phosphorylated and Nonphosphorylated Breakpoint Cluster Region-Abelson (Bcr-Abl) Kinase and Overcomes Clinically Acquired Mutation-Induced Resistance against Imatinib".JOURNAL OF MEDICINAL CHEMISTRY 56.3(2013).
个性服务
查看访问统计
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。


©版权所有 ©2017 CSpace - Powered by CSpace